000178883 001__ 178883
000178883 005__ 20240229143558.0
000178883 0247_ $$2doi$$a10.1016/j.radonc.2022.02.009
000178883 0247_ $$2pmid$$apmid:35182686
000178883 0247_ $$2ISSN$$a0167-8140
000178883 0247_ $$2ISSN$$a1879-0887
000178883 0247_ $$2altmetric$$aaltmetric:123162135
000178883 037__ $$aDKFZ-2022-00318
000178883 041__ $$aEnglish
000178883 082__ $$a610
000178883 1001_ $$0P:(DE-HGF)0$$aLöck, Steffen$$b0
000178883 245__ $$aBiomarker signatures for primary radiochemotherapy of locally advanced HNSCC - hypothesis generation on a multicentre cohort of the DKTK-ROG.
000178883 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2022
000178883 3367_ $$2DRIVER$$aarticle
000178883 3367_ $$2DataCite$$aOutput Types/Journal article
000178883 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1651579637_6244
000178883 3367_ $$2BibTeX$$aARTICLE
000178883 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178883 3367_ $$00$$2EndNote$$aJournal Article
000178883 500__ $$a2022 Apr;169:8-14
000178883 520__ $$aTo develop prognostic biomarker signatures for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by primary radiochemotherapy (RCTx) based on previously published molecular analyses of the retrospective biomarker study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG).In previous studies on the retrospective DKTK-ROG HNSCC cohort treated with primary RCTx, the following clinical parameters and biomarkers were evaluated and found to be significantly associated with loco-regional tumour control (LRC) or overall survival (OS): tumour volume, p16 status, expression of cancer stem cell markers CD44 and SLC3A2, expressions of hypoxia-associated gene signatures, tumour mutational burden (TMB), single nucleotide polymorphisms (SNPs) in the ERCC2 gene (rs1799793, rs13181) and ERCC5 gene (rs17655) as well as the expression of CXCR4, SDF-1 and CD8. These biomarkers were combined in multivariable modelling using Cox-regression with backward variable selection.A baseline signature containing the widely accepted parameters tumour volume, p16 status, cancer stem cell marker expression (CD44) and hypoxia-associated gene expression has been defined, representing the main hypothesis of the study. Furthermore, the baseline signature was extended by additional prognostic biomarkers and a data-driven signature without any pre-hypothesis was generated for both endpoints. In these signatures, the SNPs rs1799793 and rs17655 as well as CXCR4, SDF-1 and SLC3A2 expression were additionally included. The signatures showed significant patient stratifications for LRC and OS.Three biomarker signatures were defined for patients with locally advanced HNSCC treated with primary RCTx for the endpoints LRC and OS. These signatures will be validated in the prospective HNprädBio study of the DKTK-ROG that recently completed recruitment, before potential application in an interventional trial.
000178883 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000178883 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178883 650_7 $$2Other$$aBiomarkers
000178883 650_7 $$2Other$$aHNSCC
000178883 650_7 $$2Other$$aPrimary radiochemotherapy
000178883 650_7 $$2Other$$aSignature
000178883 650_7 $$2Other$$aValidation
000178883 7001_ $$0P:(DE-He78)81b719227985a27b1b77ed6766094319$$aLinge, Annett$$b1
000178883 7001_ $$0P:(DE-HGF)0$$aLohaus, Fabian$$b2
000178883 7001_ $$0P:(DE-He78)8bff76ab3cfe753721744ece2dfa32e5$$aEbert, Nadja$$b3$$udkfz
000178883 7001_ $$aGudziol, Volker$$b4
000178883 7001_ $$0P:(DE-HGF)0$$aNowak, Alexander$$b5
000178883 7001_ $$0P:(DE-HGF)0$$aTinhofer, Ingeborg$$b6
000178883 7001_ $$0P:(DE-HGF)0$$aKalinauskaite, Goda$$b7
000178883 7001_ $$0P:(DE-HGF)0$$aGuberina, Maja$$b8
000178883 7001_ $$0P:(DE-HGF)0$$aStuschke, Martin$$b9
000178883 7001_ $$0P:(DE-HGF)0$$aBalermpas, Panagiotis$$b10
000178883 7001_ $$0P:(DE-HGF)0$$avon der Grün, Jens$$b11
000178883 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b12
000178883 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b13$$udkfz
000178883 7001_ $$0P:(DE-HGF)0$$aGanswindt, Ute$$b14
000178883 7001_ $$0P:(DE-HGF)0$$aBelka, Claus$$b15
000178883 7001_ $$0P:(DE-HGF)0$$aPeeken, Jan C$$b16
000178883 7001_ $$0P:(DE-HGF)0$$aCombs, Stephanie E$$b17
000178883 7001_ $$0P:(DE-HGF)0$$aDe-Colle, Chiara$$b18
000178883 7001_ $$0P:(DE-HGF)0$$aZips, Daniel$$b19
000178883 7001_ $$0P:(DE-HGF)0$$aBaretton, Gustavo B$$b20
000178883 7001_ $$0P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aKrause, Mechthild$$b21$$udkfz
000178883 7001_ $$0P:(DE-He78)933f7d725ac87378f459623783585a1f$$aBaumann, Michael$$b22$$udkfz
000178883 7001_ $$0P:(DE-HGF)0$$aDKTK-ROG$$b23
000178883 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/j.radonc.2022.02.009$$gp. S0167814022000949$$p8-14$$tRadiotherapy and oncology$$v169$$x0167-8140$$y2022
000178883 909CO $$ooai:inrepo02.dkfz.de:178883$$pVDB
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)81b719227985a27b1b77ed6766094319$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8bff76ab3cfe753721744ece2dfa32e5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)933f7d725ac87378f459623783585a1f$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000178883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000178883 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000178883 9141_ $$y2022
000178883 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-31
000178883 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-31
000178883 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-31
000178883 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-29$$wger
000178883 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2021$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-29
000178883 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bRADIOTHER ONCOL : 2021$$d2022-11-29
000178883 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK DD zentral$$x0
000178883 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK BE zentral$$x1
000178883 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK ED ES zentral$$x2
000178883 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK FM zentral$$x3
000178883 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x4
000178883 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x5
000178883 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x6
000178883 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK MU LMU zentral$$x7
000178883 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK TU zentral$$x8
000178883 9201_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie/Radiobiologie$$x9
000178883 980__ $$ajournal
000178883 980__ $$aVDB
000178883 980__ $$aI:(DE-He78)DD01-20160331
000178883 980__ $$aI:(DE-He78)BE01-20160331
000178883 980__ $$aI:(DE-He78)ED01-20160331
000178883 980__ $$aI:(DE-He78)FM01-20160331
000178883 980__ $$aI:(DE-He78)FR01-20160331
000178883 980__ $$aI:(DE-He78)E050-20160331
000178883 980__ $$aI:(DE-He78)HD01-20160331
000178883 980__ $$aI:(DE-He78)MU01-20160331
000178883 980__ $$aI:(DE-He78)TU01-20160331
000178883 980__ $$aI:(DE-He78)E220-20160331
000178883 980__ $$aUNRESTRICTED